Summary of the webcast held on December 16, 2024
17/12/2024 – AB Science provides a summary of the webcast held on December 16, 2024
AB Science webcast of December 16, 2024
16/12/2024 – Presentation of the AB Science webcast held on December 16, 2024
Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
11/12/2024 – AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis
Revenues for the first half of 2024 and update on AB Science’s activities
10/10/2024 – AB Science today reports its revenues for the first half of 2024 and provides an update on its activities
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million euros
09/10/2024 – AB Science announces today that it has completed the settlement and delivery of the capital increase announced on September 30, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial report
30/09/2024 – The Company will publish its financial report for the first half of 2024 on Monday 7 October 2024
AB Science announces the success of a 5.0 million euros capital increase
30/09/2024 – AB Science announces today the success of a capital increase by private placement for an amount of 5 million euros
AB Science provides an update on the microtubule program AB8939
26/09/2024 – AB Science today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement